Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former “String Of Pearls” Strategist Tabbed To Lead Teva’s Continuing Diversification

This article was originally published in The Pink Sheet Daily

Executive Summary

Jeremy Levin, who left Bristol-Myers Squibb on Jan. 1, will succeed outgoing Teva CEO Shlomo Yanai in May, as the Israeli generics giant seeks to increase its emphasis on branded drugs.

You may also be interested in...



New Teva CEO’s Initial Priorities Are Manufacturing, Copaxone, R&D

Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.

Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers

Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.

Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?

The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel